Benziodarone

Summary

Benziodarone (CHEMBL232201) is an approved small molecule (ATC C01DX04); indicated across 1 condition including cardiovascular disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: C01DX04 (+1 more)
• Indications: 1 condition
• Chemistry: 518.08 Da · C17H12I2O3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL232201
Name	Benziodarone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	6237
ATC	C01DX04, C01DX54
Molecular formula	C17H12I2O3
Molecular weight	518.08
InChIKey	CZCHIEJNWPNBDE-UHFFFAOYSA-N

SMILES: CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)O)I

IUPAC name: (2-ethyl-1-benzofuran-3-yl)-(4-hydroxy-3,5-diiodophenyl)methanone

Also known as: Amplivix, Benciodarona, Benziodarone, L 2329, L-2329, NSC-82133, SID29216089, benziodarone, SID144205346, BENZIODARONE, SID170465852

Patent coverage: 360 distinct patent families (1,341 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 1,339 (100%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Prelamin-A/C, 4’-phosphopantetheinyl transferase ffp, Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Progesterone receptor, Menin/Histone-lysine N-methyltransferase MLL, 5-hydroxytryptamine receptor 1A, Prostaglandin G/H synthase 1, Sodium-dependent noradrenaline transporter, Adenosine receptor A1, Mu-type opioid receptor, D(3) dopamine receptor, Sodium-dependent dopamine transporter, 3’,5’-cyclic-AMP phosphodiesterase 4A, Histamine H3 receptor, Transthyretin, Gamma-aminobutyric acid receptor subunit alpha-1, Protein phosphatase EYA3, Baculoviral IAP repeat-containing protein 5.

Bioactivity

ChEMBL activities: 16 potent at pChembl ≥ 5 of 27 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
TTR	7.11	Kd	78	nM	CHEMBL_ACT_25987489
TTR	6.39	Kd	410	nM	CHEMBL_ACT_25481502
PDE4A	5.62	AC50	2370	nM	CHEMBL_ACT_25207114
EYA3	5.47	IC50	3400	nM	CHEMBL_ACT_18715764
EYA3	5.47	IC50	3400	nM	CHEMBL_ACT_19360996
EYA3	5.47	IC50	3400	nM	CHEMBL_ACT_27629072
PGR	5.37	AC50	4270	nM	CHEMBL_ACT_25204318
TTR	5.35	IC50	4500	nM	CHEMBL_ACT_25481487
ABCB11	5.2	AC50	6300	nM	CHEMBL_ACT_25126945
BIRC5	5.1	Kd	8000	nM	CHEMBL_ACT_1962244
PTGS1	5.08	AC50	8330	nM	CHEMBL_ACT_25205251
DRD3	5.07	AC50	8590	nM	CHEMBL_ACT_25194549
TTR	5.05	EC50	8900	nM	CHEMBL_ACT_25987471
OPRM1	5.02	AC50	9640	nM	CHEMBL_ACT_25158202
DRD1	5	AC50	10030	nM	CHEMBL_ACT_25115237
SLC6A3	5	AC50	9960	nM	CHEMBL_ACT_25124986

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
cardiovascular disorder	4	MONDO:0004995	EFO:0000319

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).